Outcome of Breast Cancer Patients with COVID-۱۹ Infection: A Report from a Tertiary Cancer Center in India
Publish place: Archives of Breast Cancer، Vol: 8، Issue: 4
Publish Year: 1400
نوع سند: مقاله ژورنالی
زبان: English
View: 124
This Paper With 6 Page And PDF Format Ready To Download
- Certificate
- من نویسنده این مقاله هستم
این Paper در بخشهای موضوعی زیر دسته بندی شده است:
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_ARCHB-8-4_006
تاریخ نمایه سازی: 9 آبان 1401
Abstract:
Introduction: There is no data on the outcome of COVID-۱۹ infection in patients with breast cancer from India. This study was done to assess the outcome of patients with breast cancer who had COVID-۱۹ infection.Methods: We analyzed patients with breast cancer who were diagnosed with COVID-۱۹ infection from May to September ۲۰۲۰ in the medical oncology department of a tertiary cancer center in India. Symptomatic patients (fever and influenza-like illness symptoms) or asymptomatic patients planned for systemic therapy were tested for COVID-۱۹ by RT-PCR.Results: A total of ۴۴۱ breast cancer patients received ۱۱۷۴ systemic therapies from May to September ۲۰۲۰. Among them, ۳۶ patients who had COVID-۱۹ infection were analyzed in detail. The majority (۸۶%) were asymptomatic at presentation. The most common symptoms were fever followed by cough. Patients were either admitted to the hospital (۵۳%) or kept in home quarantine (۴۷%). Patients who received oxygen, non-invasive assisted ventilation (NIV), and mechanical ventilation (MV) were ۸%, ۳%, and ۳%, respectively. The median duration of hospitalization and home quarantine was ۱۱ days and ۱۹ days, respectively. The recovery of patients with COVID-۱۹ infection was ۹۴%. The median duration to clearing SARS-COV-۲ by RT-PCR was ۱۹ days. The total/all-cause mortality was ۶% (n=۲). The mortality due to COVID-۱۹ infection was ۳% (n=۱). Subsequently, ۸۹% were restarted on systemic therapy. The median delay in restarting systemic therapy was ۲۳ days.Conclusion: Systemic therapy can be safely administered during the ongoing COVID-۱۹ pandemic.
Keywords:
Authors
Indhuja Muthiah Vaikundaraja
Department of Medical Oncology, Cancer Institute (WIA), Chennai, India
Makikandan Dhanushkodi
Department of Medical Oncology, Cancer Institute (WIA), Chennai, India
Venkatraman Radhakrishnan
Department of Medical Oncology, Cancer Institute (WIA), Chennai, India
Jayachanran Perumal Kalaiyarasi
Department of Medical Oncology, Cancer Institute (WIA), Chennai, India
Gangothri Selvarajan
Department of Medical Oncology, Cancer Institute (WIA), Chennai, India
Siva Sree Kesana
Department of Medical Oncology, Cancer Institute (WIA), Chennai, India